CY1111526T1 - HSV NS5B CYCLOPROPYL SUSPENDED INHIBITIONS - Google Patents
HSV NS5B CYCLOPROPYL SUSPENDED INHIBITIONSInfo
- Publication number
- CY1111526T1 CY1111526T1 CY20111100539T CY111100539T CY1111526T1 CY 1111526 T1 CY1111526 T1 CY 1111526T1 CY 20111100539 T CY20111100539 T CY 20111100539T CY 111100539 T CY111100539 T CY 111100539T CY 1111526 T1 CY1111526 T1 CY 1111526T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ns5b
- inhibitions
- hsv
- cyclopropyl
- suspended
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η εφεύρεση περικλείει ενώσεις του τύπου (I) καθώς επίσης συνθέσεις και μεθόδους χρήσης των ενώσεων. Οι ενώσεις έχουν δραστικότητα έναντι του ιού ηπατίτιδας C (HCV) και είναι χρήσιμες στην θεραπεία εκείνων που έχουν προσβληθεί από HCV.The invention includes compounds of formula (I) as well as compositions and methods of use of the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in the treatment of those infected with HCV.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80112506P | 2006-05-17 | 2006-05-17 | |
US80200506P | 2006-05-19 | 2006-05-19 | |
US85208406P | 2006-10-16 | 2006-10-16 | |
US89475707P | 2007-03-14 | 2007-03-14 | |
EP07761873A EP2024375B1 (en) | 2006-05-17 | 2007-05-04 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
US201261000699P | 2012-09-11 | 2012-09-11 | |
US201361000839P | 2013-06-26 | 2013-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111526T1 true CY1111526T1 (en) | 2016-02-10 |
Family
ID=38512732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100539T CY1111526T1 (en) | 2006-05-17 | 2011-06-03 | HSV NS5B CYCLOPROPYL SUSPENDED INHIBITIONS |
Country Status (25)
Country | Link |
---|---|
US (1) | US7456166B2 (en) |
EP (1) | EP2024375B1 (en) |
JP (1) | JP5284952B2 (en) |
KR (1) | KR101417145B1 (en) |
AR (1) | AR061008A1 (en) |
AT (1) | ATE501156T1 (en) |
AU (1) | AU2007253998B2 (en) |
BR (1) | BRPI0711821A2 (en) |
CA (1) | CA2651690C (en) |
CY (1) | CY1111526T1 (en) |
DE (1) | DE602007013036D1 (en) |
DK (1) | DK2024375T3 (en) |
EA (1) | EA015286B1 (en) |
HK (1) | HK1122814A1 (en) |
HR (1) | HRP20110194T1 (en) |
IL (1) | IL195025A (en) |
MX (1) | MX2008014435A (en) |
NO (1) | NO341663B1 (en) |
NZ (1) | NZ572555A (en) |
PE (1) | PE20080070A1 (en) |
PL (1) | PL2024375T3 (en) |
SI (1) | SI2024375T1 (en) |
TW (1) | TWI401244B (en) |
WO (1) | WO2007136982A1 (en) |
ZA (1) | ZA200809548B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5-membered fused heterocyclic compound and use thereof as hcv polymerase inhibitor |
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
CN101490054B (en) * | 2006-05-25 | 2012-05-16 | 百时美施贵宝公司 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7541352B2 (en) * | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
EP2121694B1 (en) | 2007-03-13 | 2014-07-16 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
JP5416710B2 (en) * | 2007-11-20 | 2014-02-12 | ブリストル−マイヤーズ スクイブ カンパニー | Cyclopropyl condensed indolobenzazepine HCVNS5B inhibitor |
US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
NZ585370A (en) | 2007-12-19 | 2012-09-28 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
PL2238142T3 (en) * | 2007-12-24 | 2012-11-30 | Janssen R&D Ireland | Macrocyclic indoles as hepatitis c virus inhibitors |
US8138171B2 (en) * | 2008-03-27 | 2012-03-20 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
WO2009120745A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
EP2280978B1 (en) * | 2008-03-27 | 2013-04-24 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
TWI454476B (en) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
JP2012514605A (en) | 2009-01-07 | 2012-06-28 | サイネクシス,インコーポレーテッド | Cyclosporine derivatives for use in the treatment of HCV and HIV infection |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
EP2585438B1 (en) | 2010-06-24 | 2014-08-20 | Janssen R&D Ireland | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID |
US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
JP2014506255A (en) | 2010-12-30 | 2014-03-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | Phenanthridine macrocyclic hepatitis C serine protease inhibitor |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
CA2879398A1 (en) * | 2012-07-18 | 2014-01-23 | Bristol-Myers Squibb Holdings Ireland | Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US753137A (en) * | 1904-02-23 | Dust-pan | ||
US752354A (en) * | 1904-02-16 | Composition post | ||
US756203A (en) * | 1903-11-14 | 1904-04-05 | Oliver E Barthel | Muffler. |
JP4143669B2 (en) | 2004-02-24 | 2008-09-03 | 日本たばこ産業株式会社 | Four-ring condensed heterocyclic compounds and their use as HCV polymerase inhibitors |
US7348425B2 (en) * | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
CA2584179C (en) | 2004-10-13 | 2013-01-29 | Wolfgang Staehle | N,n'-diphenylurea derivatives which are suitable as kinase inhibitors |
PE20060607A1 (en) * | 2004-10-26 | 2006-07-14 | Angeletti P Ist Richerche Bio | TETRACYCLIC INDEOL DERIVATIVES AS ANTIVIRAL AGENTS |
GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
GB0608928D0 (en) * | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
-
2007
- 2007-05-03 US US11/743,921 patent/US7456166B2/en not_active Expired - Fee Related
- 2007-05-04 KR KR1020087027866A patent/KR101417145B1/en active IP Right Grant
- 2007-05-04 AU AU2007253998A patent/AU2007253998B2/en not_active Ceased
- 2007-05-04 CA CA2651690A patent/CA2651690C/en not_active Expired - Fee Related
- 2007-05-04 PL PL07761873T patent/PL2024375T3/en unknown
- 2007-05-04 JP JP2009511151A patent/JP5284952B2/en active Active
- 2007-05-04 SI SI200730612T patent/SI2024375T1/en unknown
- 2007-05-04 DK DK07761873.4T patent/DK2024375T3/en active
- 2007-05-04 MX MX2008014435A patent/MX2008014435A/en active IP Right Grant
- 2007-05-04 EP EP07761873A patent/EP2024375B1/en active Active
- 2007-05-04 AT AT07761873T patent/ATE501156T1/en active
- 2007-05-04 NZ NZ572555A patent/NZ572555A/en unknown
- 2007-05-04 DE DE602007013036T patent/DE602007013036D1/en active Active
- 2007-05-04 EA EA200802346A patent/EA015286B1/en not_active IP Right Cessation
- 2007-05-04 WO PCT/US2007/068209 patent/WO2007136982A1/en active Application Filing
- 2007-05-04 BR BRPI0711821-0A patent/BRPI0711821A2/en not_active IP Right Cessation
- 2007-05-15 PE PE2007000585A patent/PE20080070A1/en active IP Right Grant
- 2007-05-17 AR ARP070102138A patent/AR061008A1/en active IP Right Grant
- 2007-05-17 TW TW096117512A patent/TWI401244B/en not_active IP Right Cessation
-
2008
- 2008-10-30 IL IL195025A patent/IL195025A/en not_active IP Right Cessation
- 2008-11-04 NO NO20084637A patent/NO341663B1/en not_active IP Right Cessation
- 2008-11-07 ZA ZA2008/09548A patent/ZA200809548B/en unknown
-
2009
- 2009-03-31 HK HK09103021.8A patent/HK1122814A1/en not_active IP Right Cessation
-
2011
- 2011-03-16 HR HR20110194T patent/HRP20110194T1/en unknown
- 2011-06-03 CY CY20111100539T patent/CY1111526T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111526T1 (en) | HSV NS5B CYCLOPROPYL SUSPENDED INHIBITIONS | |
CY1111423T1 (en) | NS5B HCV Suspensions | |
DE602007006796D1 (en) | CYCLOPROPYL-FUSED INDIGENOUS ZAZEPINE HCV NS5B HEMMER | |
CY1109671T1 (en) | INHIBITIONS OF THE HCV PROTECTION NS3 | |
CY1113752T1 (en) | CINOXALINE MACROCYCLICAL COMPOUNDS AS HCV NS3 SUSPENDED PROTEINS | |
DK2209789T3 (en) | Cyclopropyl-condensed indolobenzazepine HCV NS5B inhibitors | |
CL2015000870A1 (en) | 2'-Chloro nucleoside analogs for HCV infection. | |
CL2009000305A1 (en) | Compounds derived from 2-aryl-substituted-1-benzofuran-3-carboxamide, ns5b polymerase inhibitors; pharmaceutical composition; and its use in the treatment of a disease caused by the hepatitis c virus (hcv). | |
GT200600262A (en) | USE OF SANGLIFERINE IN HCV (HEPATITIS VIRUS "C") | |
CY1114298T1 (en) | MODIFIED LIMITED DIFFERENYL PRODUCTS FOR USE AS USEFUL C Virus Suspensions | |
TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
CL2011002426A1 (en) | Compounds derived from substituted benzo-diazole pyrrolidine, inhibitors of the function of the ns5a protein encoded by the hepatitis c virus (vhc); pharmaceutical composition; and its use for the treatment of a vhc infection. | |
WO2007140200A3 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
ATE522532T1 (en) | COMPOUNDS FOR TREATING HEPATITIS C | |
CL2011002453A1 (en) | Compounds derived from diazol or oxazol-pyrrole or substituted condensed pyrrolcyclopropyl, inhibitors of the function of the ns5a protein encoded by the hepatitis c virus (vhc); pharmaceutical composition; and its use for the treatment of a vhc infection. | |
ATE474827T1 (en) | HCV REPLICATION INHIBITORS | |
EA200600498A1 (en) | MACROCYCLIC PEPTIDES THAT EXPRESS ANTI-VIRUS ACTIVITY AGAINST THE HEPATITIS C VIRUS | |
CY1111050T1 (en) | PHOSPHONES, MONO-PHOSPHONAMIDES, BISPHOSPHONAMIDES FOR THE TREATMENT OF VIRUS DISEASES | |
BRPI0514176A (en) | hcv replication inhibitors | |
CR11310A (en) | Spiro-Pyrrolidines and their use against infection by the Hepatitis C virus (HCV) and by the Human Immunodeficiency virus (HIV) | |
CL2004000270A1 (en) | COMPOUNDS DERIVED FROM PIRAZOL, ITS ADDITION SALTS ACIDS, HIV DISORDERS AND GENETICALLY RELATED VIRUSES. HYDRATES, SOLVATES; PHARMACEUTICAL COMPOSITIONS; AND ITS USE IN THE TREATMENT OF GENETICALLY RELATED HIV DISORDERS AND VIRUSES. | |
MX2010001416A (en) | Compounds for the treatment of hepatitis c. | |
DE602008004317D1 (en) | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | |
ATE505473T1 (en) | CYCLOPROPYL-CONDENSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | |
ATE551343T1 (en) | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C |